279 related articles for article (PubMed ID: 17855539)
1. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
Ambrose Z; Palmer S; Boltz VF; Kearney M; Larsen K; Polacino P; Flanary L; Oswald K; Piatak M; Smedley J; Shao W; Bischofberger N; Maldarelli F; Kimata JT; Mellors JW; Hu SL; Coffin JM; Lifson JD; KewalRamani VN
J Virol; 2007 Nov; 81(22):12145-55. PubMed ID: 17855539
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
3. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Van Rompay KK; Johnson JA; Blackwood EJ; Singh RP; Lipscomb J; Matthews TB; Marthas ML; Pedersen NC; Bischofberger N; Heneine W; North TW
Retrovirology; 2007 Apr; 4():25. PubMed ID: 17417971
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.
Hofman MJ; Higgins J; Matthews TB; Pedersen NC; Tan C; Schinazi RF; North TW
Antimicrob Agents Chemother; 2004 Sep; 48(9):3483-90. PubMed ID: 15328115
[TBL] [Abstract][Full Text] [Related]
5. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
8. A simian-human immunodeficiency virus carrying the rt gene from Chinese CRF01_AE strain of HIV is sensitive to nucleoside reverse transcriptase inhibitors and has a highly genetic stability in vivo.
Wang W; Yao N; Ju B; Dong Z; Cong Z; Jiang H; Qin C; Wei Q
Microbes Infect; 2014 Jun; 16(6):461-71. PubMed ID: 24709063
[TBL] [Abstract][Full Text] [Related]
9. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
10. [Resistance profile of rilpivirine].
Imaz A; García F; di Yacovo S; Llibre JM
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
[TBL] [Abstract][Full Text] [Related]
11. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy.
Kearney M; Spindler J; Shao W; Maldarelli F; Palmer S; Hu SL; Lifson JD; KewalRamani VN; Mellors JW; Coffin JM; Ambrose Z
J Virol; 2011 Jan; 85(2):1067-76. PubMed ID: 21084490
[TBL] [Abstract][Full Text] [Related]
12. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.
North TW; Van Rompay KK; Higgins J; Matthews TB; Wadford DA; Pedersen NC; Schinazi RF
J Virol; 2005 Jun; 79(12):7349-54. PubMed ID: 15919889
[TBL] [Abstract][Full Text] [Related]
13. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.
Shao W; Kearney M; Maldarelli F; Mellors JW; Stephens RM; Lifson JD; KewalRamani VN; Ambrose Z; Coffin JM; Palmer SE
Retrovirology; 2009 Nov; 6():101. PubMed ID: 19889213
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
15. An in vivo model for HIV resistance development.
Zuber B; Böttiger D; Benthin R; ten Haaft P; Heeney J; Wahren B; Oberg B
AIDS Res Hum Retroviruses; 2001 May; 17(7):631-5. PubMed ID: 11375059
[TBL] [Abstract][Full Text] [Related]
16. Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.
Kauffman RC; Villalobos A; Bowen JH; Adamson L; Schinazi RF
PLoS One; 2014; 9(2):e88258. PubMed ID: 24505452
[TBL] [Abstract][Full Text] [Related]
17. In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients.
Gianotti N; Galli L; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Lazzarin A; Clementi M; Castagna A
New Microbiol; 2005 Oct; 28(4):319-26. PubMed ID: 16386016
[TBL] [Abstract][Full Text] [Related]
18. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection.
Mori K; Yasutomi Y; Sawada S; Villinger F; Sugama K; Rosenwith B; Heeney JL; Uberla K; Yamazaki S; Ansari AA; Rübsamen-Waigmann H
J Virol; 2000 Jul; 74(13):5747-53. PubMed ID: 10846052
[TBL] [Abstract][Full Text] [Related]
19. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
Chetchotisakd P; Anunnatsiri S; Kiertiburanakul S; Sutthent R; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Horsakulthai M; Chasombat S; Ruxrungtham K;
J Int Assoc Physicians AIDS Care (Chic); 2006 Dec; 5(4):152-6. PubMed ID: 17101807
[TBL] [Abstract][Full Text] [Related]
20. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
